27
Participants
Start Date
November 14, 2014
Primary Completion Date
August 31, 2016
Study Completion Date
August 31, 2016
selinexor
"* 60 mg dose twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle; dose may be increased to 80 mg after Cycle 1 unless clinically contraindicated (Protocol V.5.0).~* 60 mg dose twice weekly on Days 1 and 3 of weeks 1-3 of each 4-week cycle; dose may be increased to 80 mg at Cycle 3 Day 1 unless clinically contraindicated (Protocol V.4.0).~* 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-3 of each 4-week cycle (Protocol V. 3.0).~* 60 mg/m² dose, based on BSA, twice weekly, on Days 1 and 3 of weeks 1-4 of each 4-week cycle (Protocol V. \< 3.0)."
Weill Cornell Medical College, New York
Winship Cancer Institute / Emory University, Atlanta
Instituto Clinico Navarra, Pamplona, Pamplona
Ohio State University Comprehensive Cancer Center, Columbus
University Hospital of Cologne, Cologne
Huntsman Cancer Institute/University of Utah, Salt Lake City
University of Arizona Cancer Center, Tucson
University of Ulm, Ulm
University of California-Los Angeles, Santa Monica
City of Hope National Medical Center, Duarte
Malopolskie Centrum Medyczne, Krakow
Copernicus Memorial Hospital, Department of Hematology, Lodz
Maria Skłodowska-Curie Institue of Oncology, Warsaw
Institut Català d'Oncologia Av., Barcelona
Hospital Vall Hebron, Barcelona
The Royal Marsden NHS Foundation Trust, Sutton
Churchill Hospital: Cancer and Haematology Centre, Oxford
Lead Sponsor
Karyopharm Therapeutics Inc
INDUSTRY